XNAS
YMAB
Market cap197mUSD
Jul 11, Last price
4.36USD
1D
-3.54%
1Q
-9.73%
IPO
-83.83%
Name
Y-mAbs Therapeutics Inc
Chart & Performance
Profile
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
Income | |||||||||
Revenues | 87,685 3.38% | 84,819 29.96% | 65,267 87.03% | ||||||
Cost of revenue | 64,241 | 65,635 | 99,139 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 23,444 | 19,184 | (33,872) | ||||||
NOPBT Margin | 26.74% | 22.62% | |||||||
Operating Taxes | (146) | 561 | 757 | ||||||
Tax Rate | 2.92% | ||||||||
NOPAT | 23,590 | 18,623 | (34,629) | ||||||
Net income | (29,666) 38.45% | (21,427) -77.76% | (96,325) 70.96% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 100 | 84 | |||||||
BB yield | -0.03% | -0.04% | |||||||
Debt | |||||||||
Debt current | 630 | 1,804 | 868 | ||||||
Long-term debt | 1,010 | 1,936 | 2,666 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | 4,012 | 6,239 | 3,052 | ||||||
Net debt | (65,594) | (74,897) | (102,228) | ||||||
Cash flow | |||||||||
Cash from operating activities | (15,714) | (27,232) | (75,921) | ||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | 4,311 | 100 | 84 | ||||||
FCF | 30,310 | 5,180 | (31,283) | ||||||
Balance | |||||||||
Cash | 67,234 | 78,637 | 105,762 | ||||||
Long term investments | |||||||||
Excess cash | 62,850 | 74,396 | 102,499 | ||||||
Stockholders' equity | (484,868) | (457,017) | (434,708) | ||||||
Invested Capital | 581,704 | 566,562 | 548,748 | ||||||
ROIC | 4.11% | 3.34% | |||||||
ROCE | 24.21% | 17.51% | |||||||
EV | |||||||||
Common stock shares outstanding | 44,329 | 43,645 | 43,704 | ||||||
Price | 7.83 14.81% | 6.82 39.75% | 4.88 -69.90% | ||||||
Market cap | 347,096 16.61% | 297,662 39.57% | 213,274 -69.53% | ||||||
EV | 281,502 | 222,765 | 111,046 | ||||||
EBITDA | 23,979 | 19,919 | (33,033) | ||||||
EV/EBITDA | 11.74 | 11.18 | |||||||
Interest | 757 | ||||||||
Interest/NOPBT |